Research

Hormonal

Weekly subcutaneous administration of Tirzepatide (5-15 mg) significantly reduces body weight and body fat percentage in non-diabetic obese patients compared to placebo, with effects comparable to bariatric surgery.

If you are obese and non-diabetic, Tirzepatide is a highly effective weekly injection that can lead to significant weight loss (up to ~21%) and fat loss, outperforming previous GLP-1 drugs. It requires a commitment to weekly injections and lifestyle changes (diet and 150 mins/week exercise), but may offer a better side-effect profile regarding nausea than older drugs due to its dual GIP/GLP-1 mechanism.

GoodSupportsHIGH confidence
Tirzepatide significantly reduced the body weight and other obesity parameters, as compared to the placebo... The degree of weight-loss of obese patients in the SURMOUNT-1 trial could only be compared to the results of using bariatric surgery.
László Gerő · Current Research in Diabetes & Obesity Journal · 2022

Why this rating

Based on a large randomized controlled trial (n=2539) with statistically significant results (p<0.001), though it is a single study analysis rather than a meta-analysis.

Source

Tirzepatide Reduced Significantly the Body Weight in Obese Patients

László Gerő · Current Research in Diabetes & Obesity Journal · 2022

DOI 10.19080/crdoj.2022.16.555930

clinical_guideline · n=2539Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →